Bayer AG announced it will cut 227 jobs connected to its Berkeley, California manufacturing operations, as it preps a new manufacturing plant in Germany.
The layoffs come after Bayer used voluntary packages to eliminate 200 more positions, as the drugmaker shifts hemophilia A patients to next-generation drugs. Bayer won FDA and European regulatory approvals last month for its latest, long-acting hemophilia treatment, Jivi.
Bayer has been phasing out Kogenate — its main hemophilia A drug manufactured in Berkeley for the past two decades — in some markets, such as Canada and parts of the European Union, as it brings online two new blood-clotting drugs.
Read the San Fran Biz Journal Coverage
[javascriptSnippet]